Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sedation describes a clinical effect characterized by reduced irritability, excitement, or consciousness, achieved by pharmacologically depressing CNS activity. Agents producing sedation enhance inhibitory neurotransmission (typically via GABA-A, glycine, or alpha-2 adrenergic receptors), diminish arousal, and may overlap with hypnosis, anxiolysis, and amnesia[2][5][6]. Sedation is a desired effect in contexts such as surgery, anxiety management, and seizure control, but is not itself a molecular entity or receptor.
Drugs used for sedation generally act as central nervous system depressants—primarily by enhancing GABAergic signaling at the GABA-A receptor (benzodiazepines, barbiturates, propofol), antagonizing orexin receptors (daridorexant), agonizing alpha-2 adrenergic receptors (dexmedetomidine), blocking H1 histamine receptors (diphenhydramine), or agonizing opioid receptors (morphine, fentanyl)[1][2][4][6][7][9][3].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sedation.